Sign inJoin waitlistJoin the waitlist

Timothy Chan

Co-Director, National Center for Regenerative Medicine, School of Medicine · Case Western Reserve University

Credentials: · · · · ·

History

National Center for Regenerative Medicine · Case Western Reserve University
Present
Center for Immunotherapy and Precision Immuno-Oncology · Case Western Reserve University
Present
Cleveland Clinic · Case Western Reserve University
Present

Radiation Oncology
Johns Hopkins Hospital
2003–2007
Mercy Medical Center
2002–2003
Johns Hopkins School of Medicine
Johns Hopkins School of Medicine
1998–2002
Harvard University
1991–1995

Research

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Science · 2015 · Last of 24 authors · Corresponding · 6,657 citations
Genetic basis for clinical response to CTLA-4 blockade in melanoma
New England Journal of Medicine · 2014 · Co-senior of 21 authors · 3,502 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations

Luc Morris
62 papers · 6 as a fellow
Nadeem Riaz
41 papers · 1 as a resident
Ari Hakimi
29 papers · 3 as a fellow
KB
Kathryn Beal
27 papers
David Solit
22 papers
Ian Ganly
21 papers
Jason Huse
19 papers
Yoshiya Yamada
19 papers
Jedd Wolchok
18 papers
RM
Robert Motzer
17 papers
CB
Cameron Brennan
16 papers
MV
Martin Voss
15 papers

Grants

Homologous Recombination Repair Pathway Mutations and Genetic Mechanisms Shaping Anti-Tumor Immunity and Immunotherapy Efficacy
National Cancer Institute · R01
Contact PI · $1.4M · Cleveland Clinic Lerner Com-Cwru
2025–2030
Case Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $85.4K · Case Western Reserve University
1997–2030
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
National Cancer Institute · U54
Contact PI · $7.8M · Cleveland Clinic Lerner Com-Cwru
2022–2027
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
National Cancer Institute · R35
Contact PI · $7M · Cleveland Clinic Lerner Com-Cwru
2018–2025

Clinical trials

EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
Principal investigator · Not yet recruiting · Phase 1
Rabi Hanna
2026–2030
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Principal investigator · Unknown · Phase 1
Tactical Therapeutics, Inc.
2010–2026